{"organizations": [], "uuid": "9a71d5718bee3076faeff8f51f5dc467906b6c3c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "https://si.wsj.net/public/resources/images/BN-XH747_3gMid_TOP_20180202190552.jpg", "site_section": "https://www.wsj.com/europe", "section_title": "The Wall Street Journal &amp; Breaking News, Business, Financial and Economic News, World News and Video", "url": "https://www.wsj.com/articles/why-sanofi-and-its-rivals-are-paying-up-for-deals-1517826600", "country": "US", "domain_rank": 387, "title": "Why Sanofi and its Rivals Are Paying Up for Deals", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "", "spam_score": 0.32, "site_type": "news", "published": "2018-02-05T19:10:00.000+02:00", "replies_count": 0, "uuid": "9a71d5718bee3076faeff8f51f5dc467906b6c3c"}, "author": "Charley Grant", "url": "https://www.wsj.com/articles/why-sanofi-and-its-rivals-are-paying-up-for-deals-1517826600", "ord_in_thread": 0, "title": "Why Sanofi and its Rivals Are Paying Up for Deals", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "sanofi", "sentiment": "negative"}]}, "highlightText": "", "language": "english", "persons": [], "text": "One of pharma’s most lucrative assets is starting to weaken. That helps explain the hot deals market.\nDiabetes management has long been one of the drug industry’s most attractive businesses, due to a large pool of patients and the ongoing nature of treatment.\nLately, however, the business has weakened. Several of the major producers of diabetes... ", "external_links": [], "published": "2018-02-05T19:10:00.000+02:00", "crawled": "2018-02-06T01:53:11.027+02:00", "highlightTitle": ""}